Inside Drug Pricing

Consumer Advocates Outraged By Paxlovid Price Hike, Suggest Govt. Exercise March-In

By Maaisha Osman / October 19, 2023 at 7:07 PM

Public health groups allege Pfizer set an exorbitant commercial list price for its COVID-19 treatment Paxlovid, which the company revealed Thursday (Oct. 19) will be $1,390 per treatment course, and are calling on the Biden administration to exercise its authority to march in on the company’s patents.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

Consumer Advocates Outraged By Paxlovid Price Hike, Suggest Govt. Exercise March-In

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.